These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
263 related items for PubMed ID: 3479250
21. Influence of fludarabine on pharmacokinetics and pharmacodynamics of cytarabine: implications for a continuous infusion schedule. Seymour JF, Huang P, Plunkett W, Gandhi V. Clin Cancer Res; 1996 Apr; 2(4):653-8. PubMed ID: 9816215 [Abstract] [Full Text] [Related]
22. A new sensitive method for determination of intracellular 1-beta-D-arabinofuranosylcytosine 5'-triphosphate content in human materials in vivo. Yamauchi T, Ueda T, Nakamura T. Cancer Res; 1996 Apr 15; 56(8):1800-4. PubMed ID: 8620496 [Abstract] [Full Text] [Related]
26. Pharmacological study of modified intermediate-dose cytarabine therapy in patients with acute myeloid leukemia. Sutoh H, Yamauchi T, Gotoh N, Sugiyama M, Ueda T. Anticancer Res; 2003 Apr 15; 23(6D):5037-42. PubMed ID: 14981964 [Abstract] [Full Text] [Related]
27. Plasma and cerebrospinal fluid pharmacokinetics of 1-beta-D-arabinofuranosylcytosine and 1-beta-D-arabinofuranosyluracil following the repeated intravenous administration of high- and intermediate-dose 1-beta-D-arabinofuranosylcytosine. Damon LE, Plunkett W, Linker CA. Cancer Res; 1991 Aug 15; 51(16):4141-5. PubMed ID: 1868435 [Abstract] [Full Text] [Related]
28. Role of dephosphorylation in accumulation of 1-beta-D-arabinofuranosylcytosine 5'-triphosphate in human lymphoblastic cell lines with reference to their drug sensitivity. Abe I, Saito S, Hori K, Suzuki M, Sato H. Cancer Res; 1982 Jul 15; 42(7):2846-51. PubMed ID: 7083175 [Abstract] [Full Text] [Related]
29. 4-demethoxydaunorubicin (idarubicin) in combination with 1-beta-D-arabinofuranosylcytosine in the treatment of relapsed or refractory acute leukemia. Berman E, Raymond V, Daghestani A, Arlin ZA, Gee TS, Kempin S, Hancock C, Williams L, Stevens YW, Clarkson BD. Cancer Res; 1989 Jan 15; 49(2):477-81. PubMed ID: 2910465 [Abstract] [Full Text] [Related]
30. Resistance to 1-beta-D-arabinofuranosylcytosine after high-dose treatment childhood lymphoblastic leukemia: isolation of a drug resistant and a sensitive cell line. Kees UR. Cancer Res; 1987 Jun 15; 47(12):3088-91. PubMed ID: 3472651 [Abstract] [Full Text] [Related]
31. Therapy of refractory/relapsed acute leukemia with cytosine arabinoside plus tetrahydrouridine (an inhibitor of cytidine deaminase)--a pilot study. Kreis W, Budman DR, Chan K, Allen SL, Schulman P, Lichtman S, Weiselberg L, Schuster M, Freeman J, Akerman S. Leukemia; 1991 Nov 15; 5(11):991-8. PubMed ID: 1961042 [Abstract] [Full Text] [Related]
32. 1-beta-D-arabinofuranosylcytosine metabolism and incorporation into DNA as determinants of in vivo murine tumor cell response. Riva CM, Rustum YM. Cancer Res; 1985 Dec 15; 45(12 Pt 1):6244-9. PubMed ID: 2998596 [Abstract] [Full Text] [Related]
33. High-dose cytosine arabinoside and daunorubicin as consolidation therapy for acute nonlymphocytic leukemia in first remission: an update. Wolff SN, Herzig RH, Phillips GL, Lazarus HM, Greer JP, Stein RS, Ray WA, Herzig GP. Semin Oncol; 1987 Jun 15; 14(2 Suppl 1):12-7. PubMed ID: 3589687 [Abstract] [Full Text] [Related]
34. Effect of dose on the pharmacokinetic and pharmacodynamic effects of cytarabine. Capizzi RL, White JC, Powell BL, Perrino F. Semin Hematol; 1991 Jul 15; 28(3 Suppl 4):54-69. PubMed ID: 1780754 [Abstract] [Full Text] [Related]
35. Pharmacology of combination chemotherapy of cytosine arabinoside (ara-C) and uracil arabinoside (ara-U) or tetrahydrouridine (THU) against murine leukemia L1210/0 in tumor-bearing mice. Avramis VI, Powell W. Cancer Invest; 1987 Jul 15; 5(4):293-9. PubMed ID: 3664332 [Abstract] [Full Text] [Related]
36. Pharmacodynamic and DNA methylation studies of high-dose 1-beta-D-arabinofuranosyl cytosine before and after in vivo 5-azacytidine treatment in pediatric patients with refractory acute lymphocytic leukemia. Avramis VI, Mecum RA, Nyce J, Steele DA, Holcenberg JS. Cancer Chemother Pharmacol; 1989 Jul 15; 24(4):203-10. PubMed ID: 2473850 [Abstract] [Full Text] [Related]
37. Modulation of 1-beta-D-arabinofuranosylcytosine metabolism by thymidine in human acute leukemia. Zittoun R, Zittoun J, Marquet J, Rustum Y, Creaven P. Cancer Res; 1985 Oct 15; 45(10):5186-92. PubMed ID: 4027995 [Abstract] [Full Text] [Related]
38. Pharmacokinetic and pharmacodynamic studies of fludarabine and cytosine arabinoside administered as loading boluses followed by continuous infusions after a phase I/II study in pediatric patients with relapsed leukemias. The Children's Cancer Group. Avramis VI, Wiersma S, Krailo MD, Ramilo-Torno LV, Sharpe A, Liu-Mares W, Kowck R, Reaman GH, Sato JK. Clin Cancer Res; 1998 Jan 15; 4(1):45-52. PubMed ID: 9516951 [Abstract] [Full Text] [Related]
39. Close correlation of 1-beta-D-arabinofuranosylcytosine 5'-triphosphate, an intracellular active metabolite, to the therapeutic efficacy of N(4)-behenoyl-1-beta-D-arabinofuranosylcytosine therapy for acute myelogenous leukemia. Yamauchi T, Kawai Y, Goto N, Kishi S, Imamura S, Yoshida A, Urasaki Y, Fukushima T, Iwasaki H, Tsutani H, Masada M, Ueda T. Jpn J Cancer Res; 2001 Sep 15; 92(9):975-82. PubMed ID: 11572766 [Abstract] [Full Text] [Related]
40. Isolation and characterization of a deoxycytidine kinase-deficient human promyelocytic leukemic cell line highly resistant to 1-beta-D- arabinofuranosylcytosine. Bhalla K, Nayak R, Grant S. Cancer Res; 1984 Nov 15; 44(11):5029-37. PubMed ID: 6091869 [Abstract] [Full Text] [Related] Page: [Previous] [Next] [New Search]